Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting
Retrieved on:
Friday, February 25, 2022
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Therapy, Gallium, Cell, Population, Peptide, Neoplasm, Molecular Therapy, IIT, Database administrator, American College, NASDAQ, Clovis Oncology, Radiation, University, Security (finance), Cancer, FAP, University of California, San Francisco, Antibody, UCSF, Private Securities Litigation Reform Act, Safety, Biomedicine, U.S. Securities and Exchange Commission, Trial of the century, Radiology, SNMMI, Isotope, TRT, View, Mesothelioma, FDA, EMA, Drug discovery, Patient, Sarcoma, CEO, Research, Society, Department, Colon, Medical imaging, Pharmaceutical industry, the LuMIERE Clinical Study, FAP-2286, Targeted Radionuclide Therapy, Clovis Oncology, THE LUMIERE CLINICAL STUDY, FAP-2286, TARGETED RADIONUCLIDE THERAPY, CLOVIS ONCOLOGY
Approximately 50 patients will be enrolled in the Phase 1 portion of the multicenter, open-label LuMIERE trial, which is currently enrolling patients with advanced solid tumors ( NCT04939610 ).
Key Points:
- Approximately 50 patients will be enrolled in the Phase 1 portion of the multicenter, open-label LuMIERE trial, which is currently enrolling patients with advanced solid tumors ( NCT04939610 ).
- Once the Phase 2 therapeutic dose is determined, Phase 2 expansion cohorts in multiple tumor types are planned for later in 2022.
- LuMIERE is a Phase 1/2 study evaluating FAP-2286 as a peptide-targeted radionuclide therapy (PTRT) targeting fibroblast activation protein, or FAP, in patients with advanced solid tumors.
- FAP-2286 is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP).